Neurimmune AG from Schlieren in the canton of Zurich, Switzerland, and the Berlin-based AICURA Medical GmbH have agreed a strategic partnership, further details of which can be found in a press release. They intend to take advantage of the latest breakthroughs in the field of AI to develop drugs for the treatment of Alzheimer’s disease. The partnership will deploy advanced AI systems to design clinical programs with the goal of improving patient outcomes and shortening drug development times, as detailed in identical press releases issued by both companies.
Neurimmune and AICURA will seek to develop and validate algorithms to predict disease status, reaction to the treatment program and potential safety risks, the press release explains. These developments will be based on the AI capabilities of AICURA and Neurimmune’s expertise in the field of neurodegenerative diseases.
“Artificial Intelligence can generate valuable insights to help develop targeted therapeutic solutions and guide clinical development of the next generation of treatments for patients with Alzheimer’s disease”, explains Roger M. Nitsch, CEO and President of the Board of Neurimmune, in the press release.
“Neurimmune is pioneering research & clinical development in neurodegenerative disease with an advancing pipeline of drug candidates and significant, multimodal data sets based on years of clinical research”, comments Daniel Lichterfeld, founder and CEO of AICURA Medical GmbH.
Neurimmune was spun-off from the University of Zurich in 2006 and is headquartered at Bio-Technopark Schlieren-Zurich. ce/gba
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space